Last reviewed · How we verify
cyclosporine and sodium carboximethycellulose
cyclosporine and sodium carboximethycellulose is a Small molecule drug developed by Universidade Federal do Rio de Janeiro. It is currently FDA-approved.
Cyclosporine and sodium carboximethycellulose, marketed by Universidade Federal do Rio de Janeiro, holds a niche position in the pharmaceutical market. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of clear primary indication and revenue data, which may limit market expansion and investor confidence.
At a glance
| Generic name | cyclosporine and sodium carboximethycellulose |
|---|---|
| Sponsor | Universidade Federal do Rio de Janeiro |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporine and sodium carboximethycellulose CI brief — competitive landscape report
- cyclosporine and sodium carboximethycellulose updates RSS · CI watch RSS
- Universidade Federal do Rio de Janeiro portfolio CI